IL6 and breast carcinoma: IL-6-induced EMT and chemoresistance have also been demonstrated in luminal breast cancers [22] via a mechanism that involves the IL-6/JAK/STAT3 signaling axis, one of the most promising therapeutic targets for cancer control under clinical investigation [23].